Christopher L Vaughan1, Tania S Douglas2, Qonita Said-Hartley3, Roland V Baasch4, James A Boonzaier4, Brian C Goemans4, John Harverson4, Michael W Mingay4, Shuaib Omar4, Raphael V Smith4, Nielen C Venter4, Heidi S Wilson4. 1. CapeRay Medical (Pty) Ltd, Suite 2, 51 Bell Crescent, Westlake Business Park, Western Cape 7945, South Africa; MRC/UCT Medical Imaging Research Unit, Faculty of Health Sciences, University of Cape Town, Observatory, Western Cape 7925, South Africa. Electronic address: kit@caperay.com. 2. CapeRay Medical (Pty) Ltd, Suite 2, 51 Bell Crescent, Westlake Business Park, Western Cape 7945, South Africa; MRC/UCT Medical Imaging Research Unit, Faculty of Health Sciences, University of Cape Town, Observatory, Western Cape 7925, South Africa. 3. Department of Radiology, Groote Schuur Hospital, Observatory, Western Cape 7925, South Africa. 4. CapeRay Medical (Pty) Ltd, Suite 2, 51 Bell Crescent, Westlake Business Park, Western Cape 7945, South Africa.
Abstract
PURPOSE: The aim of this study was to test a novel dual-modality imaging system that combines full-field digital mammography (FFDM) and automated breast ultrasound (ABUS) in a single platform. Our Aceso system, named after the Greek goddess of healing, was specifically designed for the early detection of cancer in women with dense breast tissue. MATERIALS AND METHODS: Aceso was first tested using two industry standards: a Contrast Detail Mammography (CDMAM) phantom as endorsed by European Reference Organisation for Quality Assured Breast Screening and Diagnostic Services was used to assess the FFDM images; and the CIRS 040GSE ultrasound phantom was imaged to evaluate the quality of the ABUS images. In addition, 58 women participated in a clinical trial: 51 were healthy volunteers aged between 40 and 65, while 7 were patients referred by the breast clinic, 6 of whom had biopsy-proven breast cancer. RESULTS: The CDMAM tests showed that the FFDM results were "acceptable" but fell short of "achievable" which was attributed to the low dose used. The ABUS images had good depth penetration (80 mm) and adequate axial resolution (0.5 mm), but the lateral resolution of 2 mm was judged to be too coarse. In a 42-year-old volunteer with extremely dense breast tissue, the ABUS modality detected a lesion (a benign cyst) that was mammographically occult in the FFDM image. For a 73-year-old patient with fatty breasts, a malignant lesion was successfully detected and co-registered in the FFDM and ABUS images. On average, each woman spent less than 11 min in the acquisition room. CONCLUSIONS: While there is room for improvement in the quality of both the FFDM and ABUS images, Aceso has demonstrated its ability to acquire clinically meaningful images for a range of women with varying breast densities and, therefore, has potential as a screening device.
PURPOSE: The aim of this study was to test a novel dual-modality imaging system that combines full-field digital mammography (FFDM) and automated breast ultrasound (ABUS) in a single platform. Our Aceso system, named after the Greek goddess of healing, was specifically designed for the early detection of cancer in women with dense breast tissue. MATERIALS AND METHODS: Aceso was first tested using two industry standards: a Contrast Detail Mammography (CDMAM) phantom as endorsed by European Reference Organisation for Quality Assured Breast Screening and Diagnostic Services was used to assess the FFDM images; and the CIRS 040GSE ultrasound phantom was imaged to evaluate the quality of the ABUS images. In addition, 58 women participated in a clinical trial: 51 were healthy volunteers aged between 40 and 65, while 7 were patients referred by the breast clinic, 6 of whom had biopsy-proven breast cancer. RESULTS: The CDMAM tests showed that the FFDM results were "acceptable" but fell short of "achievable" which was attributed to the low dose used. The ABUS images had good depth penetration (80 mm) and adequate axial resolution (0.5 mm), but the lateral resolution of 2 mm was judged to be too coarse. In a 42-year-old volunteer with extremely dense breast tissue, the ABUS modality detected a lesion (a benign cyst) that was mammographically occult in the FFDM image. For a 73-year-old patient with fatty breasts, a malignant lesion was successfully detected and co-registered in the FFDM and ABUS images. On average, each woman spent less than 11 min in the acquisition room. CONCLUSIONS: While there is room for improvement in the quality of both the FFDM and ABUS images, Aceso has demonstrated its ability to acquire clinically meaningful images for a range of women with varying breast densities and, therefore, has potential as a screening device.
Authors: Avice O'Connell; David L Conover; Yan Zhang; Posy Seifert; Wende Logan-Young; Chuen-Fu Linda Lin; Lawrence Sahler; Ruola Ning Journal: AJR Am J Roentgenol Date: 2010-08 Impact factor: 3.959
Authors: Wendie A Berg; Jeffrey D Blume; Jean B Cormack; Ellen B Mendelson; Daniel Lehrer; Marcela Böhm-Vélez; Etta D Pisano; Roberta A Jong; W Phil Evans; Marilyn J Morton; Mary C Mahoney; Linda Hovanessian Larsen; Richard G Barr; Dione M Farria; Helga S Marques; Karan Boparai Journal: JAMA Date: 2008-05-14 Impact factor: 56.272
Authors: Fritz K W Schaefer; A Waldmann; A Katalinic; C Wefelnberg; M Heller; W Jonat; I Schreer Journal: Eur Radiol Date: 2009-11-05 Impact factor: 5.315
Authors: Monika Nothacker; Volker Duda; Markus Hahn; Mathias Warm; Friedrich Degenhardt; Helmut Madjar; Susanne Weinbrenner; Ute-Susann Albert Journal: BMC Cancer Date: 2009-09-20 Impact factor: 4.430
Authors: Eric D Larson; Won-Mean Lee; Marilyn A Roubidoux; Mitchell M Goodsitt; Chris Lashbrook; Cynthia E Davis; Oliver D Kripfgans; Paul L Carson Journal: Ultrasound Med Biol Date: 2018-01-05 Impact factor: 2.998
Authors: Benedikt Schaefgen; Marija Juskic; Madeleine Hertel; Richard G Barr; Marcus Radicke; Anne Stieber; André Hennigs; Fabian Riedel; Christof Sohn; Joerg Heil; Michael Golatta Journal: Arch Gynecol Obstet Date: 2021-05-10 Impact factor: 2.344